GlassScriptPhysician profile
Ahad Ashraf
NPI 1053637025
$1,977.04
in general payments reported to CMS, 2019-2025
13 companies · $202 in 2025
The $202 reported for 2025 was more than what 76% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $189 · 2021: $266 · 2022: $277 · 2023: $226 · 2024: $293 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $807.72 | 2021-2025 | Teflaro, Avycaz, Dalvance |
| Janssen Pharmaceuticals, INC | $386.81 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $232.10 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $174.09 | 2021-2024 | Firdapse |
| Pfizer INC. | $104.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $75.45 | 2019-2022 | |
| Allergan, INC. | $69.92 | 2019-2020 | |
| Smith+Nephew, INC. | $36.11 | 2025 | Collagenase Santyl |
| Astrazeneca Pharmaceuticals LP | $20.50 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.37 | 2021 | |
| Melinta Therapeutics, LLC | $19.90 | 2019 | |
| Gilead Sciences, INC. | $16.95 | 2024 | Veklury |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahad Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.